Clinical Trial Update: Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3

View source ↗

Summary

Clinical trial update notes a completed study of an early add-on combination of a GLP-1 receptor agonist and an SGLT2 inhibitor in people with cardiovascular-ki…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Chronic Kidney Disease
• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• GLP-1 receptor agonist
• SGLT2 inhibitor

Snippet

Sponsor: Chung Shan Medical University | Conditions: Cardiovascular-kidney-metabolic Syndrome, Cardiovascular Disease Risk Factor | Status: COMPLETED